ALLOGENE THERAPEUTICS INC. - COMMON STOCK

Allogene Therapeutics Announces Participation in Two Upcoming Investor Conferences

02 Mar 2023 08:30:00 By Nasdaq GlobeNewswire

Allogene Therapeutics Announces Publication of Industry-Advancing Case Study on Chromosomal Rearrangement in Molecular Therapy 

01 Mar 2023 08:30:00 By Nasdaq GlobeNewswire

Allogene Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Business Update

28 Feb 2023 16:02:00 By Nasdaq GlobeNewswire

Allogene Therapeutics to Report Fourth Quarter and Year-End 2022 Financial Results on February 28, 2023

21 Feb 2023 08:30:00 By Nasdaq GlobeNewswire

Allogene Therapeutics Presents Data on Dagger™, a Next Generation AlloCAR T™ Platform Technology

01 Feb 2023 14:55:08 By Nasdaq GlobeNewswire

Allogene Therapeutics Publishes Preclinical Data in Clinical Cancer Research Supporting DLL3 as a Potential AlloCAR T™ Target for Small Cell Lung Cancer

25 Jan 2023 08:30:00 By Nasdaq GlobeNewswire

Allogene Therapeutics Announces Publication in Nature Medicine of Data from its Phase 1 UNIVERSAL Study of ALLO-715 for the Treatment of Relapsed/Refractory Multiple Myeloma

24 Jan 2023 08:30:16 By Nasdaq GlobeNewswire

Allogene Therapeutics Announces Participation in Two Upcoming Investor Conferences

17 Jan 2023 16:05:24 By Nasdaq GlobeNewswire

Allogene Therapeutics to Present at the 41st Annual J.P. Morgan Healthcare Conference

04 Jan 2023 08:30:00 By Nasdaq GlobeNewswire

Allogene Appoints Zachary J. Roberts, M.D., Ph.D. as Executive Vice President of Research & Development

03 Jan 2023 08:00:02 By Nasdaq GlobeNewswire

Allogene Therapeutics R&D Showcase Features Hematologic and Solid Tumor Advances Across its AlloCAR T™ Platform

29 Nov 2022 15:30:12 By Nasdaq GlobeNewswire

Allogene Therapeutics Unveils Novel Approach to Generate Engineered AlloCAR T™ Cells to Control Immune Rejection at the Annual Meeting of the Society for Immunotherapy of Cancer

10 Nov 2022 09:00:02 By Nasdaq GlobeNewswire

Allogene Therapeutics To Host Research & Development Showcase and Participate in Five Upcoming Investor Conferences

09 Nov 2022 08:30:00 By Nasdaq GlobeNewswire

Allogene Therapeutics Announces Poster Presentation of Its Phase 1 UNIVERSAL Trial in Multiple Myeloma at the 64th Annual Meeting of the American Society of Hematology

03 Nov 2022 09:04:36 By Nasdaq GlobeNewswire

Allogene Therapeutics Reports Third Quarter 2022 Financial Results and Announces Investor R&D Showcase

02 Nov 2022 16:02:00 By Nasdaq GlobeNewswire

Allogene Overland Biopharm Completes Buildout of cGMP Manufacturing Facility in Shanghai to Support the Development of AlloCAR T™ Products in Asia

31 Oct 2022 08:30:00 By Nasdaq GlobeNewswire

Allogene Therapeutics to Report Third Quarter 2022 Financial Results on November 2, 2022

26 Oct 2022 08:30:00 By Nasdaq GlobeNewswire

Allogene Therapeutics Launches CAR T Together™, a First-of-its-Kind Initiative with Leading Oncologists Nationwide, Focused on Accelerating Development and Clinical Trial Recruitment for “Off-The-Shelf” Allogeneic Cell Therapy Investigational Products

11 Oct 2022 08:30:00 By Nasdaq GlobeNewswire

Allogene Therapeutics Initiates Industry’s First Allogeneic CAR T Phase 2 Trial

06 Oct 2022 16:15:00 By Nasdaq GlobeNewswire

Allogene Therapeutics Announces Participation in the Jefferies Cell and Genetic Medicine Summit

23 Sep 2022 08:30:00 By Nasdaq GlobeNewswire